3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
5
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Solid Tumors Harboring a BRAF V600 Mutation
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced BRAF Mutant Cancers
1
Interventions
Gemcitabine
97
130-nm albumin-bound paclitaxel
47
Albumin-Bound Paclitaxel
36
Oxaliplatin
27
Fluorouracil
26
Capecitabine
20
Taxes
19
Leucovorin
19
pembrolizumab
18
Cyclophosphamide
18
Irinotecan
16
Bevacizumab
12
fludarabine
11
Nivolumab
11
Cetuximab
11
Cisplatin
10
durvalumab
8
Radiotherapy
8
spartalizumab
7
aldesleukin
7
Erlotinib Hydrochloride
7
Drug Therapy
7
avelumab
6
Radiosurgery
6
Paclitaxel
6
irinotecan sucrosofate
5
folfirinox
5
Ipilimumab
5
Injections
5
ALT-803
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pancreatic Neoplasms
×
encorafenib
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled